Sorsa Tia, Pollesello Piero, Rosevear Paul R, Drakenberg Torbjörn, Kilpeläinen Ilkka
Discovery Biology, Orion Pharma, P.O. Box 65, FIN-02101 Espoo, Finland.
Eur J Pharmacol. 2004 Feb 13;486(1):1-8. doi: 10.1016/j.ejphar.2003.12.006.
The effects of the Ca(2+) sensitizer levosimendan and that of its stereoisomer dextrosimendan on the cardiac contractile apparatus were studied using skinned fibers obtained from guinea pig hearts. Levosimendan was found to be more effective than dextrosimendan in this model. The respective concentrations of levosimendan and dextrosimendan at EC(50) were 0.3 and 3 microM. In order to explain the difference in efficacy as Ca(2+) sensitizers, the binding of the two stereoisomers on cardiac troponin C was studied by nuclear magnetic resonance in the absence and presence of two peptides of cardiac troponin I. The two stereoisomers interacted with both domains of cardiac troponin C in the absence of cardiac troponin I. In the presence of cardiac troponin I-(32-79) and cardiac troponin I-(128-180), the binding of both levosimendan and dextrosimendan to the C-terminal domain of cardiac troponin C was blocked and only the binding to the N-terminal domain was observable. Differences in the overall binding behavior of the two isomers to cardiac troponin C were highlighted in order to discuss their structure to activity relation. Our data are consistent with the notion that the action of levosimendan as a Ca(2+) sensitizer and positive inotrope relates to its stereoselective binding to Ca(2+)-saturated cardiac troponin C.
使用从豚鼠心脏获取的脱细胞纤维,研究了钙离子敏化剂左西孟旦及其立体异构体右西孟旦对心脏收缩装置的影响。在该模型中,发现左西孟旦比右西孟旦更有效。左西孟旦和右西孟旦在半数有效浓度(EC50)时的各自浓度分别为0.3和3微摩尔。为了解释作为钙离子敏化剂在疗效上的差异,通过核磁共振研究了这两种立体异构体在不存在和存在两种心肌肌钙蛋白I肽的情况下与心肌肌钙蛋白C的结合。在不存在心肌肌钙蛋白I的情况下,这两种立体异构体与心肌肌钙蛋白C的两个结构域相互作用。在存在心肌肌钙蛋白I-(32-79)和心肌肌钙蛋白I-(128-180)的情况下,左西孟旦和右西孟旦与心肌肌钙蛋白C C末端结构域的结合均被阻断,仅观察到与N末端结构域的结合。突出了这两种异构体与心肌肌钙蛋白C总体结合行为的差异,以便讨论它们的结构与活性关系。我们的数据与以下观点一致,即左西孟旦作为钙离子敏化剂和正性肌力药物的作用与其对钙离子饱和的心肌肌钙蛋白C的立体选择性结合有关。